Short answer
DaVita (DVA) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3.4B (up 6.0% year over year) with net income of $198M.
Q1 2026 key financials · XBRL
- Revenue
- $3.4B
- +6.0% YoY
- Net income
- $198M
- +21.2% YoY
- Operating margin
- 14.1%
- EPS (diluted)
- $2.87
- +43.5% YoY
Source: XBRL data from the DaVita (DVA) Q1 2026 10-Q on SEC EDGAR. USD.
DaVita Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Near-term headwinds: OBBBA, reimbursement changes, tariffs, supply disruptions, labor costs, cyber incident impacts
- Outlook uncertainty: treatment volumes, commercial-payor mix, government funding, MA enrollment, competition, and federal shutdowns
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases and other disclosures
- Repurchase authorization: $1,456 million remaining as of May 5, 2026
- Share repurchases: 3,005 shares purchased at average $133.70 during first-quarter 2026
- Credit-facility constraint: Repurchases remain subject to limitations under current senior secured credit facilities
- Executive trading plan: Up to 6,455 shares potentially sold by Kathleen A. Waters through November 15, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DaVita quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.